MediCrops® AG

MediCrops® AG is a leading Swiss healthcare venture dedicated to shaping the future of digital pharma and health innovation. As a fully integrated ecosystem, MediCrops® AG combines telemedicine, digital health platforms, pharmaceutical compounding, and licensed distribution to deliver safe, personalized, and scalable treatments for complex medical conditions. Their primary address is Bahnweg 11, Freienbach, Schwyz 8808, CH, with additional locations at Kurfürstendamm 207-208, Mindspace Office 1031, Berlin, Berlin 10719, DE, and Steinenberg 23, Basel, BS 4051, CH. MediCrops® AG focuses on prescription-based therapies, specializing in cannabinoid medicine produced under the highest pharmaceutical quality standards.

With a state-of-the-art infrastructure and an expanding network of medical experts, MediCrops® AG empowers physicians and patients with access to individualized treatment options, accessible anytime, anywhere. MediCrops® AG is committed to advancing healthcare through technology and regulated precision, ensuring a significant impact on patient care. MediCrops® AG is dedicated to building Europe’s next-generation digital health leader.

MediCrops® AG continually strives to innovate and enhance the pharmaceutical standard of care. Through pioneering research and strategic partnerships, MediCrops® AG is well-positioned to meet the evolving needs of the healthcare industry. We invite the management team at MediCrops® AG to create a customized and exclusive company showcase and product listing on our platform to further highlight their offerings and expertise.